Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 254, Issue 8, 2016, Pages 1497-1503

  Kim, Hyesun ^a,b   Lee, Sung Chul ^a   Kwon, Kye Yoon ^a   Lee, Ji Hwan ^a   Koh, Hyoung Jun ^a   Byeon, Suk Ho ^a   Kim, Sung Soo ^a   Kim, Min ^a   Lee, Christopher Seungkyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Siloan Eye Hospital   (South Korea)

Author keywords

Anti vascular endothelial growth factor; Polypoidal choroidal vasculopathy; Subfoveal choroidal thickness

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGED; ARTICLE; BIOMICROSCOPY; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLIT LAMP; SUBFOVEAL CHOROIDAL THICKNESS; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CHOROID; CHOROID DISEASES; DIAGNOSTIC IMAGING; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHOROID; CHOROID DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84949521646     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-015-3221-x     Document Type: Article

References (33)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10(1):1–8
2. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55(6):501–515
3. Tamura H, Tsujikawa A, Otani A et al (2007) Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography. Br J Ophthalmol 91(9):1152–1159
4. Laude A, Cackett PD, Vithana EN et al (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29(1):19–29
5. Sasahara M, Tsujikawa A, Musashi K et al (2006) Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 142(4):601–607
6. Jirarattanasopa P, Ooto S, Nakata I et al (2012) Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 53(7):3663–3672
7. Sonoda S, Sakamoto T, Otsuka H et al (2013) Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC Ophthalmol 13:43
8. Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118(5):840–845
9. Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S (2011) Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249(8):1123–1128
10. Nishide T, Hayakawa N, Nakanishi M et al (2013) Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy. Graefes Arch Clin Exp Ophthalmol 251(10):2415–2420
11. Maruko I, Iida T, Oyamada H, Sugano Y, Ojima A, Sekiryu T (2013) Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol 156(3):548–556
12. Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156(4):652–660
13. Hikichi T, Higuchi M, Matsushita T et al (2012) One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 154(1):117–124, e111
14. Saito M, Iida T, Kano M (2011) Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina 31(8):1589–1597
15. Hirami Y, Tsujikawa A, Otani A et al (2007) Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 27(3):335–341
16. Matsumiya W, Honda S, Kusuhara S, Tsukahara Y, Negi A (2013) Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol 13:10
17. Hikichi T, Ohtsuka H, Higuchi M et al (2010) Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 150(5):674–682, e671
18. Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182–199
19. Kang HM, Kim YM, Koh HJ (2013) Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 155(3):438–447, e431
20. Cho HJ, Kim HS, Jang YS et al (2013) Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am J Ophthalmol 156(6):1192–1200, e1191
21. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S (2013) Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol 155(2):305–313, e301
22. Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453–1464
23. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7 (1991) Ophthalmology 98(5 Suppl):741–756
24. Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146(4):496–500
25. Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC (2014) Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 157(5):1013–1021
26. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117(9):1792–1799
27. Park HS, Kim IT (2012) Clinical characteristics of polypoidal choroidal vasculopathy associated with chronic central serous chorioretionopathy. Korean J Ophthalmol 26(1):15–20
28. Ueta T, Obata R, Inoue Y et al (2009) Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 116(12):2400–2406
29. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388–1398
30. Usui S, Ikuno Y, Akiba M et al (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci 53:2300–2307
31. Lee SW, Yu SY, Seo KH, Kim ES, Kwak HW (2014) Diurnal variation in choroidal thickness in relation to sex, axial length, and baseline choroidal thickness in healthy Korean subjects. Retina 34(2):385–393
32. Han YS, Lim HB, Lee SH, Kim JY (2015) Diurnal Variation in Choroidal and Retinal Thickness of the Early Treatment of Diabetic Retinopathy Study Macular Subfields Determined Using Swept-Source Optical Coherence Tomography. Ophthalmologica 233:192–197
33. Tan CS, Ouyang Y, Ruiz H, Sadda SR (2012) Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:261–266